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ORIGINAL INVESTIGATION

Efficacy and safety of bempedoic
acid for prevention of cardiovascular
events and diabetes: a systematic review
and meta‑analysis
Xing Wang1†, Yu Zhang1,2†, Huiwen Tan1, Peng Wang2, Xi Zha2, Weelic Chong3, Liangxue Zhou1*
and Fang Fang1*

Abstract
Background: Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking.
Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events
and diabetes.
Methods: We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language
restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials
comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events
in statin-intolerant patients with hypercholesterolemia. The primary outcomes were major adverse cardiac events, and
percent change in LDL-C.
Results: We identified 11 trials including a total of 4391 participants. Bempedoic acid use was associated with a
reduction in composite cardiovascular outcome (RR 0.75, 95% CI 0.56–0.99; I2 = 0%). Bempedoic acid reduced LDL-C
levels (MD − 22.91, 95% CI − 27.35 to − 18.47; I2 = 99%), and similarly reduced CRP levels (MD -24.70, 95% CI − 32.10
to − 17.30; I2 = 53%). Bempedoic acid was associated with a reduction in rates of new-onset or worsening diabetes
(RR 0.65, 95% CI 0.44–0.96; I2 = 23%).
Conclusions: Bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascular events and diabetes.
Keywords: Bempedoic acid, Prevention, Cardiovascular disease, Meta-analysis
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Background
Cardiovascular diseases are among the principal causes
of mortality, accounting for about 1 in 3 deaths in the
United States [1]. Therefore, preventive interventions
from the established risk factors for such diseases are a
high priority. Statins are the standard of care for lower
cholesterol levels and prevention of cardiovascular
events. However, statin intolerance is reported to prevalent from 7 to 29%, with the predominant symptoms
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being muscle-related side effects [2]. Inability to tolerate statins leads to uncontrolled cholesterol levels and
insufficient cardiovascular risk reduction. To reduce cardiovascular risk in these patients, the 2018 multisociety
guidelines advocate the addition of non-statin agents [3].
Bempedoic acid (Esperion Therapeutics Inc, Ann
Arbor, MI), as a small molecule inhibitor of ATP-citrate
lyase, is an oral, once-daily, first-in-class drug being
developed for the treatment of hyperlipidemia by inhibiting cholesterol synthesis [4]. Randomized clinical trials have shown the efficacy of bempedoic acid treatment
on lowering low-density lipoprotein–cholesterol [5–17].
Thus, the drug has been listed in the future perspectives of 2019 ESC/EAS Guidelines for new approaches
to reduce low-density lipoprotein cholesterol [18]. In
2020, the Food and Drug Administration (FDA) has
approved bempedoic acid for the treatment of adults who
require additional low-density lipoprotein-cholesterol
lowering [19], and European Medicines Agency (EMA)
has recommended approval bempedoic acid to treat
adults with primary hypercholesterolemia and mixed
dyslipidemia [20]. However, the benefites of bempedoic
acid are limited, because current trials have not proved
the potential benefits of bempedoic acid use for prevention of cardiovascular events [7, 13]. The primary criticisms of those trials have been small numbers of events,
raising the probability of a type II error. We performed
the systematic review and meta-analysis to evaluate the
potential benefit and safety of bempedoic acid use for the
prevention of cardiovascular events.

Methods
Protocol and guidance

The protocol of this study was registered in Open Science
Framework (https://osf.io/va34s). The methods of reporting systematic review followed PRISMA guidelines [21].
Eligibility criteria

Inclusion Criteria: Eligible studies met the following
PICOS (Patients, Intervention, Comparison Outcomes,
and Study design) criteria: (1) Population: statin-intolerant patients or patients that are on statins, with hypercholesterolemia (age ≥ 18); (2) Intervention: bempedoic
acid; (3) Comparison intervention: placebo or no treatment; (4) Outcomes: at least one outcome of interest had
to be reported. (5) Study design: randomized controlled
trials.
Outcomes

The primary outcomes were major adverse cardiac event
(defined as a composite of cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization. Follow-up of
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the cardiovascular events should be at least 12 months
or 48 weeks), and percent change from baseline to the
respective study endpoints in low-density lipoprotein
cholesterol (LDL-C). Secondary event outcomes were
cardiovascular death, myocardial infarction, nonfatal
stroke, hospitalization for unstable angina, coronary
revascularization, percent change in C-reactive protein
(CRP), and new-onset or worsening diabetes. Secondary safety outcomes were any adverse event, serious
adverse event, muscular-related adverse event, decrease
in glomerular filtration rate, increase in blood creatinine, increase in blood uric acid, gout, neurocognitive
disorders, ALT or AST > 3 × ULN, and creatine kinase
(CK) > 5 × ULN. These outcomes may be defined in individual trials with variations.
Information sources and search strategy

We searched the electronic databases Medline, Embase,
Cochrane Library of Clinical Trials from inception until
March 3, 2020. Relevant clinical trial registries (ClinicalTrials.gov) were consulted regarding any ongoing studies or the availability of completed studies with reported
results. We also checked the reference lists of eligible
studies and screened scientific abstracts. We did not
use any language or publication status restrictions. The
details of the search strategy conducted are presented in
Additional file 1. Table S1.
Study selection

Two authors (YZ and XW) evaluated eligibility independently based on titles and abstracts of all reports
retrieved in the electronic search. They screened the
full text for potentially relevant trials when both agreed
that a citation met the eligibility criteria. Discrepancies
were resolved by consensus among the study team. The
corresponding authors were contacted to obtain missing information and unpublished data when needed, to
assess the inclusion criteria or when suitable data were
not available.
Data collection process

Data were extracted using piloted forms, independently
and in duplicate by the two authors (YZ and XW). Discrepancies were resolved by consensus among the study
team.
Assessment of risk of bias and quality of evidence

Two authors (YZ and XW) examined eligible studies
independently using the Cochrane risk of bias assessment tool [22]. We assessed the following domains for
each study: (1) random sequence generation, (2) allocation sequence concealment, (3) blinding of participants
and personnel, (4) blinding of outcome assessment, (5)
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completeness of outcome data, (6) selective reporting,
and (7) other sources of bias. Each domain was assessed
as either low, unclear, or high risk of bias. The highest
risk of bias for any criteria was used to reflect the overall
risk of bias for the study.
Two authors (YZ and XW) used the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE) approach to rate the quality of evidence and
generate absolute estimates of effect for the outcomes,
taking into account study limitations (risk of bias), inconsistency, imprecision, indirectness, and publication bias
[23].
Statistical analysis

The statistical analyses were performed using RevMan
(5.3.3; The Cochrane Collaboration) and the meta package in R (version 3.4.3; R Project for Statistical Computing). Random-effects models were used for all outcomes.
Dichotomous variables were analyzed using the Mantel–Haenszel method and were expressed as risk ratios
(RR). Continuous variables were expressed as mean differences. Statistical significance testing was 2-sided and
P < 0.05 was considered statistically significant. Heterogeneity was assessed using with the χ2 test and the I2 test,
with I2 > 50% being considered substantial [24]. The possibility of publication bias was evaluated by a visual estimate of the funnel plot and by the regression tests Egger
test, Begg test, and Harbord test when ten or more trials
were pooled [25]. Analyses for all outcomes were done on
an intention-to-treat basis.
Sensitivity analyses

Sensitivity analyses were conducted for the primary outcome by (1) excluding trials with unclear or higher risk
of bias (2) using inverse variance method; and (3) using
fixed-effect models.
Subgroup analysis

We planned subgroup analyses for major adverse cardiac event and percent change in LDL-C for the following variables: (1) whether patients with a history of statin
intolerance; (2) whether treatment with a combination
of bempedoic acid and ezetimibe; (3) whether treatment
with a combination of bempedoic acid and maximally
tolerated statin therapy; (4) whether treatment with
stains as background therapy.

Results
Description of included studies

We identified 106 records. After screening, eleven trials
[5–15] with a total of 4391 participants met our inclusion criteria. Figure 1 details the study selection process.
Descriptive details of the eligible trials are presented in
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Table 1. Study sizes ranged from 56 to 2230 participants;
the mean age ranged from 53.3 to 64.7 years; the percentage of female ranged from 26.1 to 63.6%. Two trials [7,
13] have a follow-up period of at least 1 year, whereas
nine trial [5, 6, 8–12, 14, 15] have follow-up periods less
than 1 year.
Risk of bias and quality of evidence

The overall quality of the 11 included trials was moderate (Figure S1 and S2 in the Additional file 1.); 6 trials [6, 7, 10, 13–15] had low risk of bias, 1 trial [8] had
unclear risk of bias, and 4 trials [5, 9, 11, 12] had high risk
of bias. Table 2 shows a summary of findings for all outcomes. The quality of evidence assessed with the GRADE
approach was high for major adverse cardiac events.
Cardiovascular events

There were 2 trials [7, 13], including a total of 3008 participants with data available regarding major adverse
cardiovascular events. Specifically, we performed a composite tally of cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina,
and coronary revascularization. The use of bempedoic
acid was associated with reductions in the composite cardiovascular outcome (RR 0.75, 95% CI 0.56–0.99; I 2 = 0%;
Fig. 2). Other cardiovascular events were reported in
Table 2. The use of bempedoic acid was not associated
with reductions in cardiovascular death, myocardial
infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization, compared
individually with placebo (Additional file 1. Figure S3–
S7). Subgroup analysis for major adverse cardiovascular
events did not detect any beneficial effect in any specific
subgroups (Additional file 1. Figure S8).
Percent change in LDL‑C and CRP

There were 9 trials [6, 8, 12, 26–31], including a total of
3957 participants with data available regarding the percent change in LDL-C from baseline to the respective
study endpoints. The pooled results showed that using
bempedoic acid resulted in lower LDL-C compared
with placebo, with a mean difference of 22.91% (95% CI
− 27.35 to − 18.47%; I2 = 99%; Fig. 3). Subgroup analysis for percent change in LDL-C revealed subgroup of
no stains using as background therapy benefit more on
LDL-C lowering (P = 0.03; Additional file Figure S9).
Seven trials including 3555 participants reported percent
change in CRP. The pooled results showed that bempedoic acid reduced CRP levels compared with placebo,
with a mean difference of 24.70% (95% CI − 32.10 to
− 17.30%; I2 = 53%; Additional file 1. Figure S10).
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Fig. 1 Flow diagram showing final included and excluded studies

For the outcome of new-onset or worsening diabetes,
four studies [7, 10, 11, 13] reported a total of 161 events
[92/2424 (3.7%) with bempedoic acid and 69/1197
(5.7%) with placebo]. The use of bempedoic acid was
associated with a reduction in new-onset or worsening
diabetes (RR 0.65, 95% CI 0.44–0.96; I2 = 23%; Fig. 4).

Bempedoic acid was not associated with an increased
incidence of any adverse event, serious adverse event
or muscle-related adverse event. Also, bempedoic
acid was not associated with increased blood creatinine, gout, neurocognitive disorders, incidence of
ALT or AST > 3 × ULN, or incidence of creatine kinase
(CK) > 5 × ULN (Additional file 1. Figure S12–S20).

Safety outcomes

Sensitivity analysis

Table 2 summarized findings of safety outcomes. Bempedoic acid was associated with elevated levels of blood
uric acid (Additional file 1. Figure S11), but not associated with a decrease in glomerular filtration rate.

Similar results were observed for the composite cardiovascular outcome in all conducted sensitivity analyses
by excluding trials with unclear or higher risk of bias,
using inverse variance method, and using fixed-effect
models (Additional file 1. Table S2).

New‑onset or worsening diabetes

Wang et al. Cardiovasc Diabetol

(2020) 19:128

Page 5 of 9

Table 1 Characteristics of studies included in the systematic review
Trial

Country Patients, n Female (%) Age, years BMI, kg/m2 Follow
Baseline
up (weeks) for LDLC(mg/dl)

Ballantyne 2013 US
Gutierrez 2014

Characteristics
of patients

Dose
of bempedoic
acid

177

44.6

57.5

28.2

12

166.2

No stain used

40, 80, or 120 mg
daily

US

60

38.3

55.7

29.9

12

126.8

No stain used

180 mg daily

Thompson 2015 US

56

50.0

63.5

29.7

12

179.05

Statin intolerant

120 mg, 180 mg,
or 240 mg

Ballantyne 2016 US

133

59.4

57.3

30.3

12

135.6

Stable statin
background
therapy

180 mg daily

Thompson 2016 US

149

71.1

59.7

29.7

12

163.9

With or without
statin intolerant

120 mg or 180 mg

Ballantyne 2018 US

269

61.3

63.8

29.8

12

127.6

Statin intolerance

180 mg daily

Laufs 2019

Germany

345

50.4

65.2

30.3

24

157.6

Statin intolerance

180 mg daily

Ray 2019

UK

2230

27.0

66.1

NR

52

103.2

Maximally
180 mg daily
tolerated statin
therapy

Ballantyne 2019 US

129

50.4

65.1

30.6

12

148.08

Maximally
180 mg daily
tolerated statin
therapy

Goldberg 2019

US

779

36.3

64.3

30.2

52

120.4

Maximally
180 mg daily
tolerated statin
therapy

Lalwani 2019

US

64

48.4

58.0

31.0

4

76.4

High-intensity
statin
background
therapy

180 mg daily

NR not reported, BMI body-mass index, LDL- low-density lipoprotein cholesterol

Discussion
In this meta-analysis of 11 RCTs enrolling 4391 patients,
the use of bempedoic acid was associated with reductions in the composite cardiovascular outcome consisting
of cardiovascular death, myocardial infarction, nonfatal
stroke, hospitalization for unstable angina, and coronary
revascularization in statin-intolerant patients with hypercholesterolemia. Moreover, bempedoic acid use was
associated with a reduced risk of diabetes.
Comparison with existing data

To the best of our knowledge, this study is the first
meta-analysis assessing the effect of bempedoic acid
on cardiovascular events. The previous meta-analysis
has evaluated the use of bempedoic acid to reduce LDL
cholesterol [17], and had analyzed 5 trials with a total of
625 patients with hypercholesterolemia, concluding that
bempedoic acid led to significantly lower LDL cholesterol
levels without adverse events. The previous review did
not assess the efficacy of bempedoic acid on cardiovascular events and may be underpowered to assess adverse
drug events due to the small sample size [17].

This study builds on the previous meta-analysis mainly
through the inclusion of two large trials [7, 13], the
CLEAR Harmony trial [13] and the CLEAR Wisdom trial
[7]. However, both trials were not designed to assess the
effect on cardiovascular events, and thus, individually did
not observe significant between-group differences in the
incidence of cardiovascular events.
Another important finding of our analysis is that bempedoic acid was associated with a reduction in new-onset
or worsening diabetes. This phenomenon may be related
to AMP-activated protein kinase (AMPK), since bempedoic acid plays a dual role in both activation of hepatic
AMPK signaling pathway and inhibitory activity against
hepatic ATP-citrate lyase (ACL) [32, 33].

Strengths and limitations
The major strength in our review is the strict methodology implemented which followed the recommendations
of the Cochrane Collaboration and PRISMA statement,
including a protocol, an up-to-date literature search and
study selection, data extraction and risk of bias assessment by two independent investigators. We also included
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Table 2 Summary of findings and strength of evidence in studies
Outcome

No.
of patients
(Trials)

Cardiovascular events

3008 (2)

Percent change of LDL-C

3957 (9)

New-onset or worsening diabetes

3621 (4)

Percent change of CRP

3555 (7)

Myocardial infarction

3008 (2)

Coronary revascularization

RR/MD (95% CI)

I2

Absolute effect estimates (per 1000)
Intervention Control Difference

0.75 [0.56, 0.99]

0%

56

− 22.91 [− 27.35, − 18.47] 99% –
0.65 [0.44, 0.96]

23% 38

74

Quality
of the evidence

− 19 [− 1, − 33] High

Moderate#

–

–

58

− 20 [− 2, − 32] Moderate§

–

–

Moderate#

0.54 [0.25, 1.15]

37% 12

22

Moderate§,#

3008 (2)

0.74 [0.50, 1.10]

0%

29

39

− 10 [− 17, 3]

Cardiovascular death

3008 (2)

1.65 [0.46, 5.98]

0%

5

3

Nonfatal stroke

3008 (2)

1.11 [0.34, 3.61]

0%

4

4

Hospitalization for unstable angina

2574 (2)

0.84 [0.41, 1.73]

51% 11

13

Any adverse event

4188 (9)

1.01 [0.97, 1.05]

40% 712

705

Serious adverse event

4184 (9)

1.06 [0.89, 1.26]

0%

126

Muscular-related adverse event

2703 (3)

1.12 [0.80, 1.56]

Decrease in glomerular filtration rate

3276 (3)

Increase in blood creatinine

3482 (4)

Increase in blood uric acid
Gout

− 24.70 [− 32.10, − 17.30] 53% –

− 10 [− 20, 4]

Moderate§

2 [− 2, 15]

Moderate§

0 [− 3, 10]

Moderate§

− 2[− 8, 9]

Low#,§

7 [− 21, 35]

Low&,#

119

7 [− 13, 31]

Moderate&

26% 120

107

13 [− 21, 60]

Moderate§

3.61 [0.81, 16.04]

0%

4

1

3 [− 1, 14]

Low*

2.15[0.81, 5.69]

0%

6

3

3 [− 1, 16]

Moderate§

1176 (3)

3.76 [1.24, 11.39]

0%

30

8

3421 (4)

2.37 [0.88, 6.36]

12% 12

5

7 [− 1, 43]

Moderate§

Neurocognitive disorders

3076 (3)

0.94 [0.41, 2.17]

0%

8

8

0 [− 5, 9]

Moderate§

ALT or AST > 3 × ULN

3382 (5)

1.97 [0.61, 6.34]

0%

6

3

3 [− 1, 14]

Moderate§

3382 (5)

1.31 [0.23, 7.50]

19% 3

2

1 [− 1, 12]

Moderate§

CK > 5 × ULN

22 [2,81]

Low*

LDL-C Low density lipoprotein cholesterol, CRP C-reactive protein, CK Creatine kinase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ULN Upper limit
of the normal range, RR Risk ratio, MD Mean difference
&

Publication bias

#

Inconsistency

§

Imprecision

*Very serious imprecision

Fig. 2 Random-effects meta-analysis of bempedoic acid on composite cardiovascular outcome

GRADE to assess the degree of certainty in pooled estimates of effect and presented absolute and relative risks.
This study has several limitations. First, the cardiovascular outcomes might be imprecise, seen as a wider CI
around the estimate of the effect, due to the relatively
few patients included. We have downgraded the quality
of evidence of these outcomes due to imprecision of the
individual studies.
Second, there is significant clinical heterogeneity in
the bempedoic acid dose utilized, duration of treatment,

and outcome definitions across the trials included in this
meta-analysis.
Third, only 2 trials reported data with 1 year of follow-up, but other trials had less. More trials with longer
follow-up are required to examine whether the benefits
of bempedoic acid are enhanced over time and whether
bempedoic acid can ultimately lower the rate of mortality.
Fourth, the small number of trials included to analyze
the major adverse cardiac events led to the inability to
detect the presence of publication bias. However, the risk
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Fig. 3 Random-effects meta-analysis of bempedoic acid on percent change in LDL-C. LDL-C Low density lipoprotein cholesterol

Fig. 4 Random-effects meta-analysis of bempedoic acid on new-onset or worsening diabetes

of publication bias was low because all trials individually
had negative results in the major adverse cardiac events.
Fifth, heterogeneity might exist in the outcome of
new-onset or worsening diabetes. The two largest trials varied in the effect point of new-onset or worsening
diabetes (RR 0.93 vs RR 0.61), with some statistical heterogeneity (I2 = 23%). We have downgraded the quality of
evidence of new-onset or worsening diabetes because of
inconsistencies.
Future research and other pharmacotherapies

The results of the present meta-analysis indicate that
more clinical trials are warranted to investigate remaining questions about the potentially beneficial effect of
bempedoic acid on cardiovascular outcomes. Major
variations in the study protocols of these trials included
in the meta-analysis indicate that the optimal dosing of
bempedoic acid remains uncertain. Likewise, it is uncertain if there are subgroups of patients who are more likely
to benefit from bempedoic acid. Moreover, longer followups could help provide much-needed data on the effectiveness on cardiovascular outcomes, long-term safety,
and tolerability of bempedoic acid.
In addition to bempedoic acid [34, 35], there are many
novel therapeutic drugs that have demonstrated the

ability to lower LDL-C levels or further reduce the risk
of major cardiovascular events in both non‑diabetic
patients and diabetic patients [36–38]. These drugs span
a variety of mechanisms, such as proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor [39, 40], peroxisome proliferators-activated receptor (PPAR) inhibitor [41, 42], and IL-1β inhibitor [43]. Many of the novel
therapeutic agents are undergoing clinical evaluation,
and some of them have already approved by the FDA.
The use of non-statin therapies for primary prevention
of hyperlipidemia in subpopulations of patients who do
not tolerate statins remain an area of active investigation,
and clinicians should still refer to existing guidelines for
initial pharmacotherapeutic selection in patients with
hyperlipidemia.

Conclusions
The use of bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascular events and DM. Morevover, bempedoic acid
resulted in a significant lowering of LDL-C level and CRP
level. More trials with longer follow-ups are needed to
confirm the overall result and identify subgroups that
benefit the most from the use of bempedoic acid.
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